J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagaraja, N. V.
Right arrow Articles by Derendorf, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagaraja, N. V.
Right arrow Articles by Derendorf, H.

PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic/Pharmacodynamic Modeling of Luteinizing Hormone (LH) Suppression and LH Surge Delay by Cetrorelix after Single and Multiple Doses in Healthy Premenopausal Women

Nelamangala V. Nagaraja, PhD, Birgit Pechstein, PhD, Katharina Erb, MD, Christine Klipping, MD, Robert Hermann, MD, Mathias Locher, PhD and Hartmut Derendorf, PhD

From the Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville (Dr. Nagaraja, Dr. Derendorf); Early Phase & Clinical Development, VIATRIS GmbH & Co. KG, Frankfurt am Main, Germany (Dr. Pechstein, Dr. Hermann, Dr. Locher); clinphase-clinical pharmacology services, Frankfurt am Main, Germany (Dr. Erb); and dinox bv, Nijmegen, the Netherlands (Dr. Klipping). Dr. Derendorf is a fellow of the American College of Clinical Pharmacology.

Cetrorelix (CET) is a potent luteinizing hormone-releasing hormone (LH-RH) antagonist and is used to prevent premature ovulation in IVF (in vitro fertilization) procedures. The objective of the present study was to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the LH suppression and LH surge delay after single doses (SD) and multiple doses (MD) of CET in healthy premenopausal women without ovarian stimulation. CET was given by subcutaneous route (SD, 0.25, 0.5, or 1 mg) on cycle day 3 and as similar multiple once-a-day doses from cycle day 3 to day 16 in two consecutive menstrual cycles. The concentration-time data of CET and LH were used for PK/PD modeling. A two-compartment model described the PK of CET with median terminal half-life estimates of 9.2 and 54.5 hours after SD and MD, respectively. An indirect-response Emax model was used to describe the LH suppression and the LH surge delay. LH suppression was linked to plasma concentrations of CET, while the delay in the LH surge was linked to the PK of CET through a hypothetical effect compartment. Since the SD regimen on day 3 did not cause significant delay, these values were used as controls in the analysis of surge delay in MD data. The IC50 (for suppression) estimate was 0.73 ng/ml for SD, and EC50 (surge delay) was 1.42 ng/ml for MD. The PK/PD model adequately described the LH suppression and the surge delay.

Address for reprints: Hartmut Derendorf, PhD, Department of Pharmaceutics, College of Pharmacy, University of Florida, SW Archer Road, P.O. Box 100494, Gainesville, FL 32610-0494.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology